Long‐term efficacy of autologous cell therapy, repeated PTA and conservative treatment in people with diabetes and chronic limb‐threatening ischaemia

Documenti analoghi

• Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
  di: Filipe A. Moura, et al.
  Pubblicazione: (2024)
• Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial
  di: Soo Heon Kwak, et al.
  Pubblicazione: (2024)
• Association of clonal haematopoiesis and diabetes with outcomes after autologous haematopoietic cell transplantation
  di: Rusha Bhandari, et al.
  Pubblicazione: (2025)
• Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
  di: Noga C. Minsky, et al.
  Pubblicazione: (2025)
• Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
  di: Stefan R. Bornstein, et al.
  Pubblicazione: (2024)